STOCK TITAN
  1. Home
  2. News
  3. GENE

Genetic Technologies Ltd. - GENE STOCK NEWS

Welcome to our dedicated news page for Genetic Technologies Ltd. (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genetic Technologies Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genetic Technologies Ltd.'s position in the market.

News
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
Rhea-AI Summary
Genetic Technologies (NASDAQ:GENE) closes a US$2 million registered direct offering and issues unregistered warrants to drive revenue, expand into new markets, and fund product research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
Genetic Technologies Announces $2 Million Registered Direct Offering
Rhea-AI Summary
Genetic Technologies announces a $2 million registered direct offering of 1,000,000 American Depositary Shares at $2.00 per share, with additional unregistered warrants to purchase up to 1,000,000 ADSs. The offering aims to raise capital for the company's operations and expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
Rhea-AI Summary
Genetic Technologies announces the establishment of a precision oncology division and the launch of a new portfolio of diagnostic tests under its geneType brand. The tests aim to improve treatment outcomes for various cancers by providing valuable information to medical oncologists. The company collaborates with the University of Melbourne to develop methylation tests, solid tumor mutation tests, and liquid biopsy tests. The global genomics market is projected to grow significantly, offering a substantial market opportunity for GeneType within the next 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
Rhea-AI Summary
Genetic Technologies reports a significant increase in sales for geneType Risk Assessment Tests, with a 543% growth in commercial tests for the 6 months ending March 31, 2024. The company's clinical adoption of geneType is expanding across 12 US States, Canada, and Australia, demonstrating a growing commitment from clinicians to offer personalized care and early disease detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
none
-
News
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Genetic Technologies is focusing on commercializing its geneType multi-risk test, while BioVie is developing therapies for neurodegeneration and liver disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
none
-
News
GTG to pilot GeneType in Breast Screen centers across the U.S.
Rhea-AI Summary
Genetic Technologies (NASDAQ: GENE) announces a clinical implementation study with breast imaging centers in New York, Miami, and Houston. The study aims to streamline care by integrating geneType into imaging centers, benefiting women at increased risk of breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.18%
Tags
none
News
EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”
Rhea-AI Summary
Genetic Technologies (NASDAQ: GENE) partners with Humanise Health to launch 'Know Your Risk' event for women's health empowerment, featuring Risk Assessment portfolio at The Langham, Pasadena, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
News
Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market
Rhea-AI Summary
Genetic Technologies (GENE) announces a successful digital strategy led by Dr. Malcolm Bohm, resulting in significant increases in social media metrics. Consumer reach is up 56.3%, content interactions up 503%, and engagement up 175%. The company predicts a surge in adoption of risk assessment tests, shifting focus from 'sickcare' to 'healthcare'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
none
-
News
GTG Global Collaborations and Innovation Update
Rhea-AI Summary
Genetic Technologies (GENE) announces its commitment to innovation through strong global academic partnerships, continuous enhancement of geneType portfolio, and expansion of risk assessment tests. Collaborations with high-profile universities, ongoing research projects, and development of new tests demonstrate GTG's dedication to improving patient care and personalized medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
none
News
GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
Rhea-AI Summary
Genetic Technologies (GENE) announces the development of a groundbreaking risk assessment test for serious diseases, incorporating over 200 high penetrant genes to identify nearly 100% of people at risk. The test covers common cancers, cardiovascular disease, and type 2 diabetes, going beyond family history to identify patients at risk of disease. This innovation aims to revolutionize personalized preventative healthcare, providing physicians and patients with unparalleled insight into individual risk profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
none
Stock GENE logo
Genetic Technologies Ltd.

Nasdaq:GENE

GENE Rankings

N/A Ranked by Market Cap
#4458 Ranked by Stock Gains
N/A Ranked by Dividends

GENE Stock Data

13.21M
101.76M
0.64%
0.3%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
Australia
Melbourne

About GENE

genetic technologies (asx: gtg, nasdaq global market: gene) is leading-edge genetic testing and reproductive services business which, together with an extensive range of international patents and allied research activities, aims at uncovering the impact of dna on health. throughout the asia pacific region, we translate specialised genetic tests into products and services that optimise the health knowledge and outcomes in humans, animals and plants.